Drug treatment of the negative symptoms of schizophrenia

European Neuropsychopharmacology

Volumn 8, Issue 1, 1998, Pages 33-42

  King, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Atypical antipsychotics; EPS; Negative symptoms; Schizophrenia; Typical antipsychotics

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SERTINDOLE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEGATIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

EID: 0031962988     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00041-2     Document Type: Article

References (63)

1. Ananth J., Djenderdjian A., Shamasunder P., Costa J., Herrera J., Sramek J. Negative symptoms: psychopathological models. J. Psychiatry Neurosci. 16:1991;12-18.
2. Arvanitis, L., 1996. Clinical profile of Seroquel (ICI 204, 636): an overview of recent clinical studies. In: Holliday, S., Ancill, R.J., MacEwan, G.W. (Eds.), Schizophrenia: Breaking down the Barriers. John Wiley, New York.
3. Barnas C., Stuppäck C.H., Miller C., Haring C., Sperner-Unterweger B., Fleischhacker W.W. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms - a double-blind trial versus haloperidol. Int. Clin. Psychopharmacol. 7:1992;23-27.
4. Barnes, T.R.E., 1994. The assessment of negative symptoms. In: Barnes, T.R.E., Nelson, H.E. (Eds.), The Assessment of Psychoses: a Practical Handbook. Chapman and Hall Medical, London. Ch. 5, pp. 51-70.
5. Beasley C.M., Tolleson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology. 4:1996;111-123.
6. Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. Neuroleptic-induced EPS: clinical perspectives with ritanserin (R55667), a new selective 5-HT2 receptor blocking agent. Curr. Ther. Res. 40:1986;492-499.
7. Bondolfi G., Baumann P., Patris M., May J.P., Billeter U., Dufour H. A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Eur. Neuropsychopharmacol. 5(3):1995;349.
8. Borison R.L., Arvanitis L.A., Miller B.G. ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J. Clin. Psychopharmacol. 16:1996;158-169.
9. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., Aubin F. Treatment of negative symptoms of schizophrenia with amisulpride. Br. J. Psychiatry. 166:1995;68-72.
10. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry. 151:1994;20-26.
11. Carmen J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int. Clin. Psychopharmacol. 10:1995;207-213.
12. Carpenter W.T., Heinrich D.W., Wagman A.M.I. Deficit and non-deficit forms of schizophrenia: the concept. Am. J. Psychiatry. 145:1988;578-583.
13. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan W., Labelle A., Beauclair L., Arnott W. A Canadian multicentre, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
14. Claus A., Bollen J., De-Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand. 85:1992;295-305.
15. Dieterle D.M., Ackenheil M., Muller-Spahn F., Kapfhammer H.-P. Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry. 20:1987;52-57.
16. Dieterle D.M., Muller-Spahn F., Ackenheil M. Efficacy and tolerance of zotepine in a double-blind comparison with perazin in schizophrenics. Fortschr. Neurol. Psychiatr. 59:1991;18-22.
17. Ereshefsky L., Tran-Johnson T.K., Watanabe M.D. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clin. Pharmacol. 9:1990;682-707.
18. Fabre L.F., Arvanitis L., Pultz J., Jones V.M., Malick J.B., Slotnick V.B. ICI 204, 636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin. Ther. 17:1995;366-378.
19. Fleischhacker W.W., Barnas C., Stuppack C.H., Unterweger B., Miller C., Hinterhuber H. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol. Bull. 25:1989;97-100.
20. Fleischhacker W.W., Unterweger B., Barnas C., Stuppack C., Hinterhuber H. Results of an open phase II study with zotepine-a new neuroleptic compound. Pharmacopsychiatry. 20:1987;64-66.
21. Hagger C., Buckley P., Kenny J.-T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
22. Hale, A., Van der Burght, M., Friberg, H.H., Wehnert, A., 1996. Dose ranging study comparing 4 doses of sertindole and 1 dose of haloperidol in schizophrenic patients. Eur. Neuropsychopharmacol. 6 (Suppl. 3), 61.
23. Harada T., Otsuki S., Fujiwara Y. Efficacy of zotepine in therapy-resistant psychoses. An open multicentre study in 8 psychiatric hospitals. Fortschr. Neurol. Psychiatr. 59:1991;41-44.
24. Harrigan, E.P., 1996. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia. Presented at the American Psychiatric Association Annual Meeting, New York, p. 229.
25. Hirsch, S.R., Link, C.G.G., Goldstein, J.M., Arvanitis, L.A., 1996. ICI 204, 636: a new atypical antipsychotic drug. Br. J. Psychiatry 168 (Suppl. 29), 45-56.
26. Høyberg O.J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielson M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr. Scand. 88:1993;395-402.
27. Hurst, B.C., Link, C.G.G., 1996. 'Seroquel' (ICI 204, 636) Efficacy in treating the negative symptoms of schizophrenia. Eur. Neuropsychopharmacol. 6 (Suppl. 4), S4-124.
28. Hwu H.-G., Tan H., Chen C.-C., Yeh L.-L. Negative symptoms at discharge and outcome in schizophrenia. Br. J. Psychiatry. 166:1995;61-67.
29. Johnson A.L., Johnson D.A.W. Peer review of 'Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol'. Br. J. Psychiatry. 166:1995;727-733.
30. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., The Clozaril Collaborative Study Group, 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch. Gen. Psychiatry 45, 789-796.
31. King D.J., Blomqvist M., Cooper S.J., Doherty M.M., Mitchell M.J., Montgomery R.C. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. Psychopharmacology. 107:1992;175-179.
32. Klieser E., Lehmann E., Tegeler J. Double-blind comparison of 3×75 mg zotepine and 3×4 mg haloperidol in acute schizophrenics. Fortsch. Neurol. Psychiatr. 59:1991;14-17.
33. Klieser, E., Lehmann, E., Kinzler, E., Wurthmann, C., Heinrich, K., 1995. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 15 (Suppl. 1), 45S-51S.
34. Lieberman, J.A., 1993. Understanding the mechanism of action of atypical antipsychotic drugs. Br. J. Psychiatry 163 (Suppl. 22), 7-18.
35. Lindenmayer, J.P., 1995. New pharmacotherapeutic modalities for negative symptoms in psychosis. Acta Psychiatr. Scand. 91 (Suppl. 388), 15-19.
36. Lindenmayer, P., Grochowski, S, Mabugat, L., 1994. Clozapine effects on positive and negative symptoms: six-month trial in treatment-refractory schizophrenics. J. Clin. Psychopharmacol. 141, 201-204.
37. MacEwan G.W. New antipsychotic medications: Do research results relate to clinical practice? Can. J. Psychiatry. 38:1993;S75-S79.
38. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 15:1994;825-835.
39. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
40. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
41. Meltzer, H.Y., 1992a. Dimensions of outcome with clozapine. Br. J. Psychiatry 160 (Suppl. 17), 46-53.
42. Meltzer, H.-Y., 1992b. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer., H.Y. (Ed.), Novel Antipsychotic Drugs. Raven Press, New York, pp. 1-13.
43. Melzer H.Y., Bastani B., Young-Kwon K., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology. 99:1989;68-72.
44. Möller, H.-J., 1995. The negative component in schizophrenia. Acta Psychiatr. Scand. 91 (Suppl. 388), 11-14.
45. Möller H.-J., van Praag H.M., Aufdembrinke B., Bailey P., Barnes T.R.E., Beck J., Bentsen H., Eich F.X., Farrow L., Fleischhacker W.W., Gerlach J., Grafford K., Hentschel B., Hertkorn A., Heylen S., Lecrubier Y., Leonard J.P., McKenna P., Maier W., Pedersen V., Rappard A., Rein W., Ryan J., Sloth Nielsen M., Stieglitz R.D., Wegener G., Wilson J. Negative symptoms in schizophrenia: considerations for clinical trials. Psychopharmacology. 115:1994;221-228.
46. Muller-Spahn F., Dieterle D., Ackenheil M. Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms. Results of an open and a double-blind controlled study. Fortschr. Neurol. Psychiatr. 59:1991;30-35.
47. Needham P.L., Atkinson J., Sill M.J., Heal D.J. Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol. Bull. 32:1996;123-128.
48. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol. 8:1994;193-195.
49. Paillère-Martinot M.-L., Lecrubier Y., Martinot L.-C., Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am. J. Psychiatry. 152:1995;130-133.
50. Peacock L., Lublin H., Gerlach J. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur. J. Pharmacol. 186:1990;49-59.
51. Petit M., Raniwalla J., Leutenegger E., Tweed J.A., Dollfus S., Kelly F. A double-blind study of zotepine vs haloperidol in schizophrenia. Psychopharmacol. Bull. 32:1996;81-87.
52. Peuskens, J., on behalf of the Risperidone Study Group, 1995. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br. J. Psychiatry 166, 712-726.
53. Pickar D., Owen R.R., Litman R.E., Konioki E., Gutierrez R., Rapaport M.H. Clinical and biologic response to clozapine in patients with schizophrenia. Arch. Gen. Psychiatry. 49:1992;345-361.
54. Puech, A.J., Lecrubier, Y., Simon, P., 1984. Pharmacological classification of benzamides. Acta Psychiatr. Scand. 69 (Suppl. 311), 139-145.
55. Reeves, K.R., 1996. The Efficacy and Safety of Two Fixed Doses of Ziprasidone in Schizophrenia. Presented at the American Psychiatric Association Annual Meeting, New York, p. 228.
56. Saletu B., Kufferle B., Anderer P., Grunberger J., Steinberger K. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur. Neuropsychopharmacol. 1:1990;27-36.
57. Saletu B., Kufferle B., Grunberger J., Foldes P., Topitz A., Anderer P. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology. 29:1994;125-135.
58. Schooler, N.R., 1994. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J. Clin. Psychiatry 55 (Suppl.5), 22-28.
59. Seeger T.F., Seymour P.A., Schmidt A.W., Zorn S.H., Schulz D.W., Lebel L.A., McLean S., Guanowsky V., Howard H.R., Lowe III J.A., Heym J. Ziprasidone (CP-88, 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 275:1995;101-113.
60. Targum S., Zborowski J., Henry M., Schmitz P., Sebree T., Wallin B. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Eur. Neuropsychopharmacol. 5(3):1995;348.
61. von Bardeleben U., Benkert O., Holsboer F. Clinical and neuroendocrine effects of zotepine - a new neuroleptic drug. Pharmacopsychiatry. 20:1987;28-34.
62. Wetzel H., von Bardeleben U., Holsboer F., Benkert O. Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy. Fortschr. Neurol. Psychiatr. 59:1991;23-29.
63. Woolley, D.W., Shaw, E., 1954. A biochemical and pharmacological suggestion about certain mental disorders. Proceedings of the National Academy of Sciences of the United States of America 40, 228-231.